Donavon Wewers, MD
Internal Medicine · Dothan, ALNPI 1972558773
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,837 of the $2,418 with a category attached, or 76.0%. 24 manufacturers reported payments, led by Novartis at 36.7% of the total. 2025 is the largest year on record at $1,123, 9.9 times the $113 reported in 2019.
Across 107 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$888
- Abbott$291
- AbbVie$203
- GSK$187
- Novo Nordisk$151
- Corcept Therapeutics$96
- plus $603 from 18 others
Across 5 payments — averaging $250,450 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$776K
- AstraZeneca$476K
What the payments were for
- Travel & lodging$53022%
- Food & beverage$1,83776%
- Other$522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $888 |
| Abbott | 23 | $291 |
| AbbVie(2 entities) | 11 | $203 |
| GSK | 11 | $187 |
| Novo Nordisk | 17 | $151 |
| Corcept Therapeutics | 7 | $96 |
| Medtronic(2 entities) | 3 | $78 |
| Astellas Pharma US Inc | 4 | $71 |
| AstraZeneca | 3 | $54 |
| Bayer | 3 | $45 |
| Grifols USA, LLC | 3 | $44 |
| Amgen | 2 | $36 |
| Pfizer | 2 | $35 |
| Insulet Corporation | 1 | $28 |
| Baxter Healthcare | 1 | $26 |
| Welch Allyn | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Amarin Pharma, Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $23 |
| Seqirus USA Inc | 1 | $20 |
| Gilead | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$2,418 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 175 | $146,314 |
| OzempicSemaglutide | 110 | $125,342 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 128 | $110,090 |
| JardianceEmpagliflozin | 131 | $96,205 |
| JanuviaSitagliptin Phosphate | 92 | $92,728 |
| MounjaroTirzepatide | 62 | $84,731 |
| XareltoRivaroxaban | 48 | $57,521 |
| MyrbetriqMirabegron | 69 | $51,275 |
| TrulicityDulaglutide | 28 | $28,735 |
| FarxigaDapagliflozin Propanediol | 39 | $28,146 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $26,471 |
| BelsomraSuvorexant | 53 | $25,957 |
| Nurtec OdtRimegepant Sulfate | 17 | $25,625 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $22,260 |
| EntrestoSacubitril/Valsartan | 32 | $21,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $35 | $171,939192 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $187 | $132,351172 claims |
| Novo NordiskOzempic | $151 | $125,342110 claims |
| Lilly USA, LLCMounjaro, Trulicity | $15 | $113,46590 claims |
| Johnson & JohnsonXarelto, Invokana | $23 | $65,00159 claims |
| Astellas Pharma US IncMyrbetriq | $71 | $51,27569 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $54 | $37,79151 claims |
| AbbVieLinzess, Namzaric | $203 | $34,98946 claims |
| NovartisEntresto | $888 | $21,94832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Dothan
- Justin HoveyDothan$67K
- Christopher MillerDothan$14K
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.